Overview: Since the treatment modalities for AML have remained relatively stagnant for decades, the approval of enasidenib is much needed as it affords patients a first-in-class, oral, single-agent targeted therapy for a difficult to treat diagnosis. This application-based continuing pharmacy education course provides a 'journal club format' discussion for pharmacists and student pharmacists to evaluate the phase 1/2 trial of enasidenib. Participate to review the safety and efficacy of enasidenib and discuss its potential in the evolving milieu of AML treatment.
We’re Your Partner for Life Long Learning. With more than 25 years in the CE business, we create education and training, partner on your education ideas, and license our learning management system. How can we serve you?
